The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.3M Compounds and 9.3K Targets. Of those, 1,372K data for 638K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

20 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.EBI
Goethe-University Frankfurt
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.EBI
Eli Lilly
Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists.EBI
Shanghai Institute of Materia Medica
Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.EBI
Glenmark Research Centre
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.EBI
Setsunan University
Discovery of a potent, orally available dual CysLT1 and CysLT2 antagonist with dicarboxylic acid.EBI
Ono Pharmaceutical
Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.EBI
Ono Pharmaceutical
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI
Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists.EBI
Zhejiang University
Modulators of leukotriene biosynthesis and receptor activation.EBI
Abbott Laboratories
The Role of Receptor Binding in Drug DiscoveryEBI
Discovery of L-740,515, a potent thienopyridine cysLT1 receptor (LTD4 receptor) antagonistEBI
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.EBI
University of Naples "Federico Ii
A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.EBI
Merck Frosst Center For Therapeutic Research
High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid.EBI
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonist.EBI
Merck Frosst Centre For Therapeutic Research
The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency.EBI
Rorer Central Research
Novel benzothiophene-, benzofuran-, and naphthalenecarboxamidotetrazoles as potential antiallergy agents.EBI